A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the
efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein
Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age
and older